MeiraGTx Stock: Hologen Partnership Makes Parkinson’s Gene Therapy Vital (NASDAQ:MGTX)

Core Insights - MeiraGTx Holdings plc (NASDAQ: MGTX) is a biotech company focused on genetic medicines with a late-stage pipeline and capabilities for end-to-end GMP manufacturing [1] Group 1: Company Overview - The main drug candidate of MeiraGTx is AAV-AIPL1, which targets congenital blindness and is progressing towards exceptional-circumstances filings [1]